IONS.US Ionis Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
29.06 USD
Close of Nov 15, 2026
27.25 86.74
Market cap
USD 4.84B
P/E
-
P/B
12.30x
ROE
-107.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IONS.US undervalued?

Graham number

The Graham number of Ionis Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ionis Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Ionis Pharmaceuticals Inc yet.

Ionis Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pe…

Full company profile